Clinical Trials on Tumors in New Zealand

Total 3211 results

Melanoma and Skin Cancer Trials Limited

Recruiting

Targeted Therapy and Avelumab in Merkel Cell Carcinoma (GoTHAM)

Metastatic Merkel Cell Carcinoma

Australia
Philip Friedlander
Genentech, Inc.

Terminated

The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma

Melanoma

United States
Memorial Sloan Kettering Cancer Center
Novartis; National Comprehensive Cancer Network

Completed

Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation

Melanoma

United States
NYU Langone Health

Terminated

A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Melanoma

United States
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Completed

Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity

Melanoma

United States
Genta Incorporated

Unknown

Abraxane and Temodar Plus Genasense in Advanced Melanoma

Melanoma

United States
Onconova Therapeutics, Inc.

Completed

Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors

Solid Tumors | Malignant Neoplasmas

United States
PharmaMar

Completed

Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors

Advanced Malignant Solid Tumors

Spain, United States
Parker Institute for Cancer Immunotherapy
Seres Therapeutics, Inc.

Completed

Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (MCGRAW)

Metastatic Melanoma

United States
InnoCare Pharma Inc.

Active, not recruiting

Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI)

Completed

Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors

Malignant Glioma | Recurrent Childhood Ependymoma | Recurrent Medulloblastoma | Recurrent Diffuse Intrinsic Pontine Glioma | Recurrent Atypical Teratoid/Rhabdoid Tumor | Refractory Diffuse Intrinsic Pontine Glioma | CNS Embryonal Tumor, Not Otherwise Specified

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Weill Medical College of Cornell University; Schering-Ploug...

Completed

Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma

Brain and Central Nervous System Tumors

United States
Impact Therapeutics, Inc.

Recruiting

Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

Solid Tumor | Advanced Solid Tumor

China, Taiwan, United States, Australia
Bristol-Myers Squibb

Withdrawn

Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma

Melanoma

United States
Atlantic Health System

Unknown

Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme

Brain and Central Nervous System Tumors

United States
Eisai Inc.

Completed

Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors

Tumors

United States
ModernaTX, Inc.
Merck Sharp & Dohme LLC

Recruiting

Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603)

Solid Tumors

United States, Australia
Memorial Sloan Kettering Cancer Center
National Institutes of Health (NIH)

Completed

Vaccination of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Human and Mouse Tyrosinase DNA Vaccines

Melanoma | Skin

United States
Onconova Therapeutics, Inc.

Completed

Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer

Neoplasms | Cancer | Advanced Cancer | Solid Tumors

United States
Instylla, Inc.

Recruiting

Instylla HES Hypervascular Tumor Pivotal Study

Hypervascular Tumors

United States, Canada
Columbia University
Pfizer

Recruiting

Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma

Pheochromocytoma | Paraganglioma

United States
Ludwig Institute for Cancer Research
Cancer Research Institute (CRI)

Completed

NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)

Malignant Melanoma

United States
Montefiore Medical Center

Completed

Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus

Uterine Cancer

United States
Incyte Corporation

Active, not recruiting

A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies

Advanced Solid Tumors

United States, Sweden, Netherlands, Norway, Denmark
MedImmune LLC

Completed

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors

Solid Tumors

United States
GT Medical Technologies, Inc.

Recruiting

Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)

Brain Tumor | Brain Tumor, Recurrent | Brain Tumor, Primary | Brain Tumor - Metastatic | Brain Tumor, Adult: Glioblastoma | Brain Tumor, Adult Meningioma

United States
Bristol-Myers Squibb

Completed

Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States

Melanoma

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma

Brain and Central Nervous System Tumors

United States
Columbia University

Terminated

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

Lymphoma | Leukemia | Anemia | Neuroblastoma | Immunodeficiencies

United States
Boehringer Ingelheim

Recruiting

A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)

Solid Tumors

Spain, Japan, United Kingdom, United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

Symptomatic Refractory Resistant Carcinoid Disease

United Kingdom, Belgium, Italy, Singapore, Austria, France, Israel, Sweden, Germany, Spain, Canada, Argentina, Poland, United States, Brazil, Norway
Memorial Sloan Kettering Cancer Center
Stanford University; Juno Therapeutics, Inc.

Active, not recruiting

Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors

Solid Tumors

United States
Memorial Sloan Kettering Cancer Center
University of Wisconsin, Madison; Duke University; AEterna Zentaris

Completed

Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors

Solid Tumors

United States
University of California, San Francisco
Agenus Inc.

Completed

HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM (HeatShock)

Brain and Central Nervous System Tumors

United States
Eisai Inc.

Completed

A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies

Cancer, Malignant Tumors

United States
Celgene
NYU Langone Health; Syneos Health; Celerion; ApoCell, Inc.

Completed

Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab

Malignant Melanoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Withdrawn

Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
Astellas Pharma Inc
OSI Pharmaceuticals; Cell Pathways

Terminated

CP-461 in the Treatment of Patients With Advanced Melanoma

Malignant Melanoma

United States
Memorial Sloan Kettering Cancer Center
Yale University; University of New Mexico

Completed

Differential Risks for Melanoma: p16 and DNA Repair

Melanoma | Skin Melanoma

United States
Eli Lilly and Company
Memorial Sloan Kettering Cancer Center

Completed

Study of gp75 Vaccine in Patients With Stage III and IV Melanoma

Malignant Melanoma

United States
Memorial Sloan Kettering Cancer Center

Completed

A Study Comparing Green Fluorescent Dye and Radioactive Dye for Sentinel Lymph Node Biopsy in Pediatric Cancers

Pediatric Patients With Solid Tumors

United States
Pfizer
Roswell Park Cancer Institute; South Texas Accelerated Research Therapeutics...

Completed

A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients

Advanced Malignant Solid Tumors

United States
Epizyme, Inc.

Completed

A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

Synovial Sarcoma | INI1-negative Tumors | Malignant Rhabdoid Tumor of Ovary | Rhabdoid Tumors

United States, France, Canada, Italy, Germany, United Kingdom, Australia, Denmark, Netherlands
Columbia University
Merck Sharp & Dohme LLC

Terminated

MRI and PET to Assess Pembrolizumab Response (MPAK)

Malignant Melanoma, Metastatic

United States
Bristol-Myers Squibb

Completed

A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US

Melanoma

United States
Bristol-Myers Squibb

Active, not recruiting

A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)

Melanoma

United States
Dartmouth-Hitchcock Medical Center

Completed

Skin Care Behaviors Among Melanoma Survivors and Their Families

Melanoma

United States
Ochsner Health System
NewLink Genetics Corporation

Unknown

A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma

Melanoma

United States
NYU Langone Health

Terminated

Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma

Metastatic Melanoma

United States
NYU Langone Health
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma

Melanoma (Skin)

United States

Clinical Trials on Tumors in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations